CD4 and Alzheimer disease: IFNγ−24 h-treated AD-MSCs reduced CD4+ T cell proliferation from 60–90% in monoculture to 7.5–10.2% (early) and 3.4–25.4% (late), indicating a dose- and passage-dependent effect.